NCT04290507: ANAPHYLASHOCK

Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit

Completed Last updated 11 March 2020

What this trial tests

trial in Anaphylaxis in 339 participants. Completed in 31 December 2019.

Timeline

1 January 2017

Primary endpoint
30 June 2019

31 December 2019

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Status	Completed
Study type	OBSERVATIONAL
Enrollment	339
Start date	1 January 2017
Primary completion	30 June 2019
Estimated completion	31 December 2019
Sites	2 locations across France

Conditions studied

• Anaphylaxis — all drugs for Anaphylaxis →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Anaphylaxis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anaphylaxis is a severe life-threatening reaction following exposure to an antigen. Its incidence is progressively increasing in the general population over years, accompanied with an increased number of hospitalizations. Although rare, this condition is often associated with a significant morbidity and mortality. The mortality rate has been recently estimated at 0.84 (95% CI, 0.79 to 0.88) per million per year in the French adult population. Age, chronic medication and cardiac or pulmonary comorbidities have been reported to increase the risk of a severe reaction. Obesity, age and cardiovascular comorbidities have been identified as risk factors for fatal anaphylaxis. However, the risk factors for death after ICU admission have not been elucidated yet.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Epidemiology and outcome of patients admitted to intensive care after anaphylaxis in France: a retrospective multicentre study.
   Guerci P, Tacquard C, Chenard L, Millard D, et al · · 2020 · cited 15× · PMID 32928517 · DOI 10.1016/j.bja.2020.08.024